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We investigated whether insulin resistance is associated with
impaired cardiac fatty acid metabolism in maintenance
hemodialysis patients without coronary artery disease. We
studied 55 nondiabetic (63711 years old) and 51 diabetic
(61710 years old) hemodialysis patients with normal
coronary arteries, using single-photon emission computed
tomography (SPECT) with an iodinated fatty acid analogue,
iodine-123-b-methyl iodophenyl-pentadecanoic acid
(123I-BMIPP), to evaluate cardiac fatty acid metabolism. SPECT
imaging was graded regionally from 0 (normal) to 4 (absence
of tracer) to calculate a summed score for 17 left ventricular
segments. Insulin resistance was determined using the
homeostasis model assessment index of insulin resistance
(HOMA-IR). HOMA-IR correlated with summed BMIPP score
in nondiabetic and diabetic patients. Stepwise multiple
regression analysis showed that HOMA-IR was independently
associated with BMIPP summed score in nondiabetic
(b¼ 0.774, t¼ 9.218, P¼ 0.0001) and diabetic patients
(b¼ 0.792, t¼ 9.079, P¼ 0.0001). Left ventricular ejection
fraction was lower in nondiabetic subjects with BMIPP
summed score of at least 6 plus HOMA-IR of at least 4 than in
others with lower values for both assessments (53.1713.8%,
n¼ 20 vs 67.779.1%, n¼ 23, P¼ 0.0002); this was also true in
diabetic subjects (50.9715.2%, n¼ 24 vs 71.0713.6%,
n¼ 11, P¼ 0.0007). Association between insulin resistance
and impaired cardiac fatty acid metabolism may contribute
to left ventricular dysfunction in patients with maintenance
hemodialysis without coronary diseases.
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Congestive heart failure is a strongly predictive, independent
risk factor for mortality in patients with end-stage renal
disease (ESRD) undergoing maintenance hemodialysis.1–3
According to the US Renal Data System, both coronary artery
disease and congestive heart failure independently predicted
mortality in a cohort of 3399 hemodialysis patients.2 In the
Hemodialysis (HEMO) study,4 a randomized multicenter
investigation of 1846 maintenance hemodialysis patients,
congestive heart failure and coronary artery disease, respec-
tively, were diagnosed in 40 and 39% of the patients. Previous
studies5,6 including one by us7 have shown that maintenance
hemodialysis patients have high prevalence of significant
coronary artery stenosis. Whereas coronary artery disease
undoubtedly is a major or cardinal cause of congestive heart
failure, left ventricular dysfunction is often recognized in
maintenance hemodialysis patients with no apparent epi-
cardial coronary artery disease. Other factors such as arterio-
venous shunt, anemia,8 hypertension,9 or chronic fluid
overload10 may contribute to heart failure, but few studies
have investigated possible abnormal cardiac fatty acid
metabolism as a cause of ventricular dysfunction in ESRD
patients without coronary disease.
Over 70% of energy expenditure required by the normal
myocardium under aerobic conditions is derived from
metabolism of free fatty acids.11 Under hypoxic or ischemic
conditions, fatty acid metabolism is suppressed and replaced
by glucose metabolism, which consumes less oxygen but is
less efficient than fatty acid metabolism in terms of adenosine
triphosphate (ATP) synthesis.12 Iodine-123-b-methyl iodo-
phenyl-pentadecanoic acid (123I-BMIPP) is a branched free
fatty acid analogue characterized by resistance to b-oxidation
in mitochondria. Single-photon emission computed tomo-
graphy (SPECT) using 123I-BMIPP as a tracer is considered to
reflect fatty acid metabolism in the heart. Because cardiac
BMIPP uptake is related to left ventricular wall motion13,14
and myocardial accumulation of BMIPP correlates well with
intracellular ATP content,15–19 which has also strong asso-
ciation with left ventricular wall motion,20,21 clinical or
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laboratory factors that decrease BMIPP SPECT imaging
intensity may contribute to left ventricular dysfunction in
hemodialysis patients who do not have coronary artery
disease. In the present study, we particularly focused on
whether insulin resistance, which is widely prevalent among
ESRD patients22–24 and is likely to cause microcirculatory
disturbance via endothelial dysfunction, is associated with
impaired cardiac fatty acid metabolism in maintenance
hemodialysis patients without coronary artery disease.
RESULTS
Factors influencing left ventricular function
In nondiabetic hemodialysis patients, left ventricular ejection
fraction (LVEF), a parameter indicating systolic left ventri-
cular function, correlated inversely with BMIPP summed
score (Figure 1a), homeostasis model assessment index
of insulin resistance (HOMA-IR) (r¼0.600, P¼ 0.0001),
plasma immunoreactive insulin (IRI) concentration (r¼
0.553, P¼ 0.0001), fasting plasma glucose concentration
(r¼0.292, P¼ 0.030), and serum high-sensitive C-reactive
protein (hs-CRP) concentration (r¼0.480, P¼ 0.0002),
but did not correlate with other clinical or laboratory factors
listed in Table 1. Among the factors correlating with LVEF,
BMIPP summed score was significantly associated with LVEF
by multiple regression analysis (Table 2) and also by multiple
regression analysis using a stepwise method (b¼0.571, t¼
5.070, P¼ 0.0001). BMIPP summed score did not correlate
with left ventricular end-diastolic dimension (Figure 1a). In
diabetic hemodialysis patients, LVEF correlated positively
with serum high-density lipoprotein (HDL)-cholesterol
concentration (r¼ 0.362, P¼ 0.009) and inversely with
BMIPP summed score (Figure 1b), HOMA-IR (r¼0.606,
P¼ 0.0001), and plasma IRI concentration (r¼0.594,
P¼ 0.0001); no correlation was found with fasting plasma
glucose concentration or other clinical or laboratory factors
listed in Table 1. Among the factors correlated with LVEF for
the subgroup with diabetes, BMIPP summed score was highly
and significantly associated with LVEF by multiple regression
analysis (Table 2), as well as multiple regression analysis using
a stepwise method (b¼0.723, t¼7.326, P¼ 0.0001).
BMIPP summed score tended to correlate with left
ventricular end-diastolic dimension (Figure 1b).
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Figure 1 | Correlation between BMIPP summed score and
LVEF or left ventricular end-diastolic dimension (LVIDd) in
(a) nondiabetic patients and (b) in diabetic patients.
Table 1 | Characteristics of study subjects
Nondiabetic group (n=55) Diabetic group (n=51)
Gender (male/female) 33/22 32/19
Age (years) 63711 61710
Dialysis duration (months) 116710 56773
Smoking (%) 43.2 41.3
Alcohol (%) 36.3 39.0
Systolic blood pressure before dialysis (mmHg) 141716 148714
Systolic blood pressure after dialysis (mmHg) 128721 136716
Body mass index (kg/m2) 22.173.3 22.573.6
Serum calcium (mmol/l) 2.2270.13 2.2070.13
Serum inorganic phosphorus (mmol/l) 1.6870.23 1.6870.23
Plasma intact parathyroid hormone (pg/ml) 2867187 2187165
Blood hemoglobin (g/l) 106.879.1 105.778.9
Serum albumin (g/l) 37.473.1 37.773.2
Serum total cholesterol (mmol/l) 4.1770.73 4.2770.78
Serum HDL-cholesterol (mmol/l) 0.9470.09 0.9270.10
Serum triglycerides (mmol/l) 1.3870.43 1.4270.44
Serum hs-CRP (mg/l) 3.0172.58 4.3472.75
Left ventricular end-diastolic dimension (mm) 50.878.4 50.377.8
Left ventricular end-systolic dimension (mm) 33.577.6 34.4710.0
LVEF (%) 61.8712.7 61.3716.6
Left ventricular mass index (g/m2) 147.8755.0 160.1766.1
HDL: high-density lipoprotein; hs-CRP: high-sensitive C-reactive protein; LVEF: left ventricular ejection fraction.
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Cardiac fatty acid metabolism and insulin resistance
Mean BMIPP summed score did not differ between
nondiabetic and diabetic patients (7.579.6 (n¼ 55) vs 9.97
8.7 (n¼ 51)). Mean fasting plasma glucose concentration was
higher in diabetic patients than in nondiabetic patients
(5.870.9 vs 5.370.5 mmol/l, P¼ 0.0005), but mean fasting
plasma IRI concentration did not differ between these groups
(19.877.5 vs 21.078.8 mU/ml). Mean HOMA-IR tended to
be greater in diabetic than in nondiabetic patients (5.472.4
vs 4.771.9, P¼ 0.086). In nondiabetic patients, BMIPP
summed score correlated positively with fasting plasma
glucose concentration (r¼ 0.330, P¼ 0.014), IRI concentra-
tion (r¼ 0.681, P¼ 0.0001), HOMA-IR, and serum hs-CRP
concentration (Figure 2a). Among factors correlated with the
BMIPP summed score, HOMA-IR was significantly asso-
ciated with BMIPP summed score by multiple regression
analysis (Table 3) as well as multiple regression analysis using
a stepwise method (b¼ 0.744, t¼ 8.116, P¼ 0.0001). In
diabetic patients, BMIPP summed score correlated positively
with serum triglycerides concentration (r¼ 0.315, P¼ 0.024),
plasma IRI concentration (r¼ 0.715, P¼ 0.0001), HOMA-IR,
and serum hs-CRP concentration (Figure 2b), and inversely
with serum HDL-cholesterol concentration (r¼0.389,
P¼ 0.005). Among factors correlated with the BMIPP
summed score, HOMA-IR was significantly associated with
BMIPP summed score by the multiple regression analysis
(Table 3), as well as multiple regression analysis using a
stepwise method (b¼ 0.792, t¼ 9.079, P¼ 0.0001). In our
previous study, a BMIPP summed score of 6 was the cutoff
value for detecting coronary artery disease in maintenance
hemodialysis patients.7 Mean LVEF was lower in the sub-
group with BMIPP summed score of 6 or more and HOMA-
IR of at least 4.0 than in the subgroup with BMIPP summed
score not exceeding 5 and HOMA-IR below 4.0 in both
nondiabetic and diabetic patients (Figure 3). In addition, the
group with left ventricular systolic dysfunction (LVEFo45%)
showed higher BMIPP summed scores (nondiabetic, 23.17
14.8 (n¼ 8) vs 3.472.8 (n¼ 27), P¼ 0.0001; diabetic,
19.7710.9 (n¼ 11) vs 5.473.3 (n¼ 24), P¼ 0.0001) and
higher HOMA-IR (nondiabetic, 7.072.0 (n¼ 8) vs 3.871.4
(n¼ 27), P¼ 0.0001; diabetic, 7.572.1 (n¼ 11) vs 4.071.6
(n¼ 24), P¼ 0.0001) than the group with normal systolic left
ventricular function (LVEFX65%). Typical images by BMIPP
SPECT of nondiabetic and diabetic hemodialysis patients
who had high BMIPP summed scores, high HOMA-IR, and
low LVEF are presented in Figure 4.
Systemic inflammation
BMIPP summed score correlated positively with serum
hs-CRP concentration in nondiabetic and diabetic patients
(Figures 2a and b). HOMA-IR correlated positively with
serum hs-CRP concentration in nondiabetic (r¼ 0.649, P¼
0.0001, n¼ 55) and diabetic patients (r¼ 0.603, P¼ 0.0001,
Table 2 | Multiple regression analysis concerning LVEF
Group b t P
Nondiabetic
BMIPP summed score 0.492 3.022 0.004
HOMA-IR 0.291 0.276 0.784
Plasma IRI 0.415 0.434 0.666
FPG 0.179 0.604 0.549
Serum hs-CRP 0.092 0.659 0.513
Diabetic
BMIPP summed score 0.688 4.207 0.0001
HOMA-IR 0.375 1.095 0.279
Plasma IRI 0.404 1.415 0.164
Serum HDL-cholesterol 0.111 0.941 0.352
LVEF: left ventricular ejection fraction; BMIPP: b-methyl iodophenyl-pentadecanoic
acid; HOMA-IR, homeostasis model assessment index of insulin resistance; IRI,
immunoreactive insulin; FPG, fasting plasma glucose; hs-CRP, high-sensitive
C-reactive protein; HDL, high-density lipoprotein.
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Figure 2 | Correlation between BMIPP summed score and HOMA-
IR or serum hs-CRP concentrations in (a) nondiabetic patients
and (b) in diabetic patients.
Table 3 | Multiple regression analysis concerning BMIPP
summed score
Group b t P
Nondiabetic
HOMA-IR 2.258 2.628 0.011
Plasma IRI 1.546 1.933 0.059
FPG 0.375 1.493 0.142
Serum hs-CRP 0.169 1.422 0.161
Diabetic
HOMA-IR 1.038 3.628 0.001
Plasma IRI 0.236 0.914 0.366
Serum hs-CRP 0.027 0.237 0.814
Serum HDL-cholesterol 0.044 0.410 0.684
Serum triglycerides 0.041 0.401 0.691
BMIPP: b-methyl iodophenyl-pentadecanoic acid; HOMA-IR, homeostasis model
assessment index of insulin resistance; IRI, immunoreactive insulin; FPG, fasting
plasma glucose; hs-CRP, high-sensitive C-reactive protein; HDL, high-density
lipoprotein.
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n¼ 51). By multiple regression analysis using a stepwise
method, HOMA-IR was strongly associated with serum
hs-CRP concentration in nondiabetic (b¼ 0.649, t¼ 6.215,
P¼ 0.0001) and diabetic patients (b¼ 0.603, t¼ 5.295,
P¼ 0.0001).
DISCUSSION
In the present study, BMIPP summed score was negatively
associated with LVEF, whereas HOMA-IR, a parameter indi-
cating insulin resistance, was positively associated with
BMIPP summed score in both nondiabetic and diabetic
hemodialysis patients with no evidence of epicardial
coronary artery disease. Further, a group of patients with
higher BMIPP summed score and HOMA-IR had lower
LVEF than a group of patients with lower BMIPP summed
score and HOMA-IR. Hemodialysis patients with systolic
left ventricular dysfunction (LVEFo45%) had higher mean
BMIPP summed scores and mean HOMA-IR than those with
normal systolic left ventricular function (LVEFX65%). When
SPECT shows reduced uptake of BMIPP (i.e. high BMIPP
summed score), cardiac fatty acid metabolism is considered
to be impaired and replaced by glucose metabolism, which
requires less oxygen consumption but produces less ATP.11,12
Efficiency of myocardial ATP synthesis is expected to be
further reduced when glucose utilization is inhibited by the
presence of insulin resistance. A combination of impaired
cardiac fatty acid metabolism with insulin resistance may
be involved in left ventricular dysfunction via reduction of
myocardial ATP content in maintenance hemodialysis
patients without coronary artery disease.
Previous investigations of metabolism and kinetics of
BMIPP in myocardial cells have shown that BMIPP SPECT
imaging indicates mainly accumulation of acetyl BMIPP in
the lipid pool of cardiomyocytes, whereas myocardial ATP
content plays a key role in the accumulation of acetyl BMIPP
in the lipid pool; decrease in myocardial ATP content leads to
reduction of BMIPP uptake in SPECT images.15–19 Therefore,
the higher values of the BMIPP summed score obtained
by BMIPP SPECT are thought to reflect not only impaired
cardiac fatty acid metabolism but also the reduction of
myocardial ATP content, which is likely to be related to left
ventricular dysfunction.18,19
ESRD patients are known to exhibit glucose intolerance,22
a reflection of insulin resistance.23,24 Tissue insensitivity to
insulin is the primary cause of insulin resistance in ESRD.25
Insulin resistance may be linked with vascular endothelial
dysfunction,26–28 which may be largely a consequence of
acquired defects of nitric oxide synthesis and intracellular
signaling.28,29 In endothelial smooth muscle cells, nitric oxide
is important for vasodilation and is degraded by reactive
oxygen species. Depleted nitric oxide and increased reactive
oxygen species induced by insulin resistance are thought to
contribute together to endothelial damage and impairment
of vasodilation. Endothelial damage and impaired vaso-
relaxation caused by insulin resistance appear to have
particularly significant effects on small arterioles, where
failure of vasodilation may result in direct tissue ischemia.
Jaap et al.30 reported an association between insulin
sensitivity and microvascular function in nondiabetic sub-
jects with fasting hyperglycemia. Serne et al.31 reported that
microvascular function as assessed by laser Doppler flow-
metry is associated with insulin sensitivity even in normal
subjects. In addition, a strong correlation between glucose-
clamp-derived indices of insulin resistance and coronary
vascular function assessed by Doppler blood flow recordings
has been demonstrated in subjects with unobstructed
coronary arteries.32 Endothelial dysfunction linked with
insulin resistance is believed to take part in the micro-
circulatory disturbance in the heart33–36 and compromise
myocardial ATP synthesis in ESRD patients.
Insulin resistance has been linked to high-normal serum
CRP concentrations.37–39 In the present study, serum hs-CRP
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Figure 3 | Differences in mean LVEF between patients with BMIPP
summed score (SS)p5 and HOMA-IRo4 and patients with BMIPP
summed score (SS)X6 and HOMA-IRX4 (a) in nondiabetic
patients and (b) in diabetic patients.
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Figure 4 | Imaging by BMIPP SPECT in maintenance hemodialysis
patients with normal coronary arteries. (a) Nondiabetic woman
(70-year-old) whose BMIPP summed score was 0, HOMA-IR was 2.3,
and LVEF was 77%. (b) Nondiabetic man (50-year-old) whose BMIPP
summed score was 26, HOMA-IR was 8.2, and LVEF was 42%.
(c) Diabetic man (64-year-old) whose BMIPP summed score was 34,
HOMA-IR was 8.6, and LVEF was 36%.
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concentration correlated positively with the HOMA-IR as
well as the BMIPP summed score in both nondiabetic and
diabetic patients. In multiple regression analysis, HOMA-IR
was strongly associated with serum hs-CRP in both groups.
Insulin resistance is thought to cause endothelial inflamma-
tion mainly via nitric oxide depletion and increased reactive
oxygen species. Subclinical elevation of serum CRP in
hemodialysis patients with normal coronary arteries may
reflect microvascular inflammation induced by insulin
resistance, which is likely to lead to microcirculatory
disturbance and impaired fatty acid metabolism in the heart.
In the present study, we did not use the ‘gold standard’ for
assessment of insulin resistance, the glucose clamp method.40
HOMA relies on the product of fasting plasma glucose and
fasting plasma insulin, and is concerned essentially with
hepatic insulin sensitivity;41,42 in contrast, the euglycemic,
hyperinsulinemic clamp technique measures insulin-
mediated glucose disposal in peripheral tissues.42 Use of
HOMA, therefore, would represent a limitation of this study.
On the other hand, many previous studies have shown that
HOMA-IR has a close correlation with clamp-measured
insulin resistance in patients with or without diabetes
mellitus,43–45 including subjects with chronic renal failure.46
Although the predictive value of HOMA-IR for insulin
resistance has been questioned among Japanese elderly
patients more than 70 years old with poorly controlled type
II diabetes,47 this point would not affect the reliability of
HOMA-IR in the present study because the diabetic patients
more than 70 years old had not been so poorly controlled;
their serum hemoglobin A1c values ranged from 4.8 to 6.5%.
Although HOMA-IR is considered a reliable method for
clinical assessment of insulin resistance in maintenance
hemodialysis patients of the present study, use of HOMA-
IR as a parameter indicating the extent of insulin resistance
could be a bias in interpreting the results of this study.
Insulin resistance determined by HOMA-IR was asso-
ciated with impaired cardiac fatty acid metabolism demon-
strated by BMIPP SPECT imaging in maintenance
hemodialysis patients with normal coronary arteries, irre-
spective of the presence or absence of diabetes mellitus.
Although fatty acid and glucose are normally major energy
substrates in the myocardium, glucose oxidation is thought
to be decreased and fatty acid oxidation enhanced in
myocardial mitochondria of patients with insulin resistance,
increasing the oxygen requirement per ATP molecule
produced. However, as ESRD patients have generally
microcirculatory disturbance in the heart, the oxygen supply
to the myocardial cells does not seem to be sufficient for
increased fatty acid oxidation, particularly in hemodialysis
patients with cardiac microcirculatory disturbance. As a
result, cardiac fatty acid metabolism as well as glucose
metabolism in myocardial cells would be impaired, and
myocardial ATP synthesis is expected to be reduced in
hemodialysis patients with insulin resistance. Because
myocardial ATP content deeply affects left ventricular wall
motion, a combination of insulin resistance with impaired
cardiac fatty acid metabolism may aggravate left ventricular
dysfunction. Understanding the relationship between insulin
resistance and impaired cardiac fatty acid metabolism is
important for establishment of congestive heart failure in
hemodialysis patients without coronary artery disease.
MATERIALS AND METHODS
Patients
We enrolled 55 nondiabetic and 51 diabetic hemodialysis patients;
patients in both these groups were undergoing maintenance
hemodialysis at Toujinkai Hospital. Characteristics of study subjects
are presented in Table 1. In all diabetic patients, type II diabetes
mellitus had been treated before initiation of hemodialysis, but they
had received neither insulin nor oral antidiabetic drugs for at least
6 months preceding the start of this study. Their mean serum
hemoglobin A1c value was 5.971.2% (4.0–10.0%); serum hemo-
globin A1c values ranged from 4.8 to 6.5% in elderly diabetic
patients more than 70 years old. All nondiabetic and diabetic
patients had been demonstrated to have normal coronary arteries by
coronary angiography performed at the Department of Interven-
tional Cardiology of the Second Kyoto Red Cross Hospital within 30
days before the blood sampling, as well as myocardial scintigraphy
and echocardiography. Quantitative coronary angiographic analysis
was performed using a validated automated edge-detection program
(CCIP-310/W; Cathex, Tokyo, Japan); maximal luminal stenosis in
coronary arteries was less than 25% in all subjects. Patients
diagnosed with acute or old myocardial infarction, idiopathic
hypertrophic, or dilated cardiomyopathy, or congestive heart failure
(New York Heart Association grades III–IV) were excluded. In
addition, patients receiving any medication likely to affect left
ventricular function, such as angiotensin I-converting enzyme
inhibitors, type-1 angiotensin II receptor blockers, a1-blockers,
b-blockers, ab-blockers, a2-agonists, or short-acting Ca blockers,
were also excluded from this study. Hemodialysis was performed
three times weekly using a dialysate containing Naþ (140 mEq/l),
Kþ (2.0 mEq/l), Cl (110 mEq/l), Ca2þ (3.0 mEq/l), Mg2þ
(1.0 mEq/l), HCO3
 (30 mEq/l), and CH3COO
 (10–15 mEq/l).
Membranes used in the dialyzer consisted of cellulose triacetate
(FB-190F; Nipro, Tokyo, Japan), surface-modified regenerated
cellulose (AMBC-20X; Asahi Medical, Tokyo, Japan), polymethyl
methacrylate (FB-2.1F; Toray Medical, Tokyo, Japan), or polysulfone
(PS-1.9UW; Kawasumi Laboratory, Tokyo, Japan). Dialysis filter
surface areas ranged from 1.8 to 2.1 m2. Histories of cigarette smoking
and alcohol consumption were ascertained by questionnaire. A
smoking habit was defined as 10 or more cigarettes per week. Alcohol
consumption was defined as alcohol intake of 20 g or more per week.
The Ethics Committee for Human Research of Toujinkai Hospital
approved this study (Committee Protocol number 6), and all patients
provided informed consent prior to participation.
Radionuclide imaging
All patients underwent resting 123I-BMIPP myocardial scintigraphy
after fasting for over 6 h on a midweek nondialysis day within 30
days after coronary angiography. A 111-MBq dose of 123I-BMIPP
(Nihon Medi-Physics, Tokyo, Japan) was injected intravenously with
patients seated. Fifteen minutes after the injection, data for SPECT
were acquired from a 64 64 matrix in 32 directions, at 61 intervals
from the 451 right anterior oblique position to the 451 left posterior
oblique position, for 30 s per direction, using a commercially
available gamma camera (Starcam 4000i; GE Medical Systems,
Kidney International (2006) 69, 553–559 557
M Nishimura et al.: Insulin resistance and cardiac fatty acids in ESRD o r i g i n a l a r t i c l e
Waukesha, WI, USA) equipped with a low-energy, all-purpose
collimator. Energy discrimination was centered at 159 keV with a
20% window. Data were entered into an online nuclear medicine data
processor (IMC12C4-5, GE Medical Systems). Tomographic images
then were constructed with short-axis, horizontal-axis, and vertical-
axis sections. Raw imaging data were reconstructed with ramp filter,
and high-frequency noise was decreased with the Butterworth-filtered
(order, 8; cutoff frequency¼ 0.82 cycle/cm) back-projection tech-
nique. The threshold level was 20%, and attenuation correction was
not used. Ventricular SPECT images were divided into 17 segments
for semiquantitative analysis according to the standard myocardial
segmentation for tomographic imaging of the heart established
by the American Heart Association. Radioactivity of each segment
was graded visually and assigned a score from 0 to 4 (0¼ normal
uptake, 1¼mildly reduced, 2¼moderately reduced, 3¼ severely
reduced, 4¼ no uptake). The sum of scores by BMIPP SPECT for 17
myocardial segments was designated the BMIPP summed score. The
same experienced technician performed scintigraphic procedures in
all cases, and the same two investigators, who had no clinical
information about the patients, interpreted the images in all cases.
Echocardiography measurements
Echocardiography was performed for each patient using a single
ultrasonographic recorder (UF-8800, Fukuda Denshi, Tokyo, Japan)
on a midweek nondialysis day within 30 days after coronary
angiography. Left ventricular dimensions and LVEF were quantified
by the biplanar Simpson’s rule, and left ventricular mass was
measured as recommended by the American Society of Echocardio-
graphy.48 Left ventricular mass was normalized to body surface area,
and is reported as the left ventricular mass index.
Biochemical and hematological determinations
Blood samples (5 ml) were obtained in the morning after an
overnight fast, on a midweek dialysis day within 30 days after
coronary angiography, after the patient had been in the supine
position for at least 10 min. Hemoglobin (and hemoglobin A1c for
diabetic patients), plasma intact parathyroid hormone concentra-
tion, and serum concentrations of albumin, total cholesterol, HDL-
cholesterol, triglycerides, and hs-CRP were determined. Total
cholesterol and triglycerides were measured enzymatically. HDL-
cholesterol was measured after precipitating apolipoprotein
B-containing lipoproteins with dextran sulfate and magnesium
chloride. Plasma intact parathyroid hormone was measured using a
chemiluminescence assay (Chemiluminescence intact PTH 100T kit;
Nichols Institute Diagnostics, San Juan Capistrano, CA, USA).
Serum hs-CRP concentration was measured using a high-sensitivity
assay kit (N-Assay LA CRP-S, D-type; Nittobo, Tokyo, Japan); the
intra- and inter-assay coefficients of variation for this assay ranged
from 0.6 to 1.6% and from 0.7 to 2.1%, respectively.
Assessment of insulin resistance
We used fasting plasma glucose and fasting plasma insulin
concentrations to calculate HOMA-IR according to the formula
HOMA-IR¼ (baseline glucose concentration (mmol/l) baseline
insulin concentration (mU/ml)/22.5). Blood was collected on the
same day as the blood collection for other biochemical and
hematological parameters. Glucose was measured by a glucose
oxidase method, and insulin was measured by a chemiluminescence
enzyme immunoassay method (LS-insulin, Eiken Chemical, Tokyo,
Japan) as IRI: the intra- and inter-assay coefficients of variation for
this assay ranged from 1.3 to 3.9% and from 1.6 to 6.8%,
respectively, and the coefficient of correlation between the
chemiluminescence enzyme immunoassay method and the radio-
immunometric assay (Insulin RIA-BEAD II, Dinabot, Tokyo, Japan)
was 0.992 (the regression equation: y¼ 0.96xþ 0.68, n¼ 208).
Statistical analysis
Values are expressed as the mean7s.d. Differences in continuous
variables between groups were evaluated by Wilcoxon’s rank-sum
test. Associations of LVEF or BMIPP summed score with other
clinical and laboratory factors were evaluated using multiple
regression analyses. All statistical tests were two-sided, with a value
for P below 0.05 defining significance. A Statistical Analysis Software
package (SPSS for Windows, versions 9.0J and 11.0J; Chicago, IL,
USA) system was used.
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